Global Celecoxib Industry Research Report, Growth Trends and Competitive Analysis 2021-2027

Celecoxib capsules (patent brand name: CELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.
The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.
Data show that more than 400 million people worldwide are currently affected by joint diseases.
The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75.
The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing.
At present, the burden of chronic diseases will increase by 40% due to the aging of the population.
As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth.
Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice.
At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years.
At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly.
It accounted for 63.39% of the global market in 2019.
As of 2019, China relies entirely on Pfizer for celecoxib imports.
Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.

In 2020, the global Celecoxib market size was US$ 1271.3 million and is forecast to 2062.6 million US in 2027, growing at a CAGR of 8.4% during the 2021-2027. In this study, 2020 has been considered as the base year and 2021 to 2027 as the forecast period to estimate the market size for Celecoxib.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Celecoxib market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Celecoxib market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Celecoxib market. Readers of the report can become informed about current and future trends of the global Celecoxib market and how they will impact market growth during the forecast period.

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Segment by Type
50mg
100mg
200mg
400mg

Segment by Application
Rheumatoid arthritis
osteoarthritis
Acute pain
Musculoskeletal pain
Other diseases

By Company
Pfizer Inc
Teva
Mylan
Apotex
Lupin
Hengrui Medicine